Asterias Biotherapeutics Inc (NYSEAMERICAN:AST)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday.
Other analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Tuesday, October 10th. ValuEngine downgraded shares of Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 4th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Asterias Biotherapeutics has a consensus rating of “Buy” and an average target price of $9.19.
Shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) opened at $2.55 on Wednesday. Asterias Biotherapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $5.70.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
What are top analysts saying about Asterias Biotherapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Asterias Biotherapeutics Inc and related companies.